Literature DB >> 25284716

GTF2I-RARA is a novel fusion transcript in a t(7;17) variant of acute promyelocytic leukaemia with clinical resistance to retinoic acid.

Ji Li1, Hai-Ying Zhong, Yang Zhang, Le Xiao, Li-Hong Bai, Su-Fang Liu, Guang-Biao Zhou, Guang-Sen Zhang.   

Abstract

Entities:  

Keywords:  GTF2I; RARA fusion gene; retinoic acid resistance; t(7; 17) translocation; variant acute promyelocytic leukaemia

Mesh：

Substances：

Year:  2014        PMID： 25284716     DOI： 10.1111/bjh.13157

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  20 in total

Review 1.  Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Authors:  Miguel A Sanz; Pierre Fenaux; Martin S Tallman; Elihu H Estey; Bob Löwenberg; Tomoki Naoe; Eva Lengfelder; Hartmut Döhner; Alan K Burnett; Sai-Juan Chen; Vikram Mathews; Harry Iland; Eduardo Rego; Hagop Kantarjian; Lionel Adès; Giuseppe Avvisati; Pau Montesinos; Uwe Platzbecker; Farhad Ravandi; Nigel H Russell; Francesco Lo-Coco
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

Review 2.  Pathophysiology of TFII-I: Old Guard Wearing New Hats.

Authors:  Ananda L Roy
Journal:  Trends Mol Med       Date:  2017-04-28       Impact factor: 11.951

3.  IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid.

Authors:  Samir Mazharuddin; Anuja Chattopadhyay; Moshe Y Levy; Robert L Redner
Journal:  Leuk Lymphoma       Date:  2018-01-19

Review 4.  Current views on the genetic landscape and management of variant acute promyelocytic leukemia.

Authors:  Xiang Zhang; Jiewen Sun; Wenjuan Yu; Jie Jin
Journal:  Biomark Res       Date:  2021-05-06

5.  A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.

Authors:  Tajana Tešan Tomić; Josefin Olausson; Annica Wilzén; Magnus Sabel; Katarina Truvé; Helene Sjögren; Sándor Dósa; Magnus Tisell; Birgitta Lannering; Fredrik Enlund; Tommy Martinsson; Pierre Åman; Frida Abel
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

Review 6.  Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment.

Authors:  Yuhui Wang; Nan Wu; Duo Liu; Yan Jin
Journal:  Curr Genomics       Date:  2017-10       Impact factor: 2.236

7.  RNF8 is responsible for ATRA resistance in variant acute promyelocytic leukemia with GTF2I/RARA fusion, and inhibition of the ubiquitin-proteasome pathway contributes to the reversion of ATRA resistance.

Authors:  Wenzhe Yan; Ji Li; Yang Zhang; Yafei Yin; Zhao Cheng; Jiayi Wang; Guoyu Hu; Sufang Liu; Yewei Wang; Yunxiao Xu; Hongling Peng; Guangsen Zhang
Journal:  Cancer Cell Int       Date:  2019-04-04       Impact factor: 5.722

8.  A novel fusion protein TBLR1-RARα acts as an oncogene to induce murine promyelocytic leukemia: identification and treatment strategies.

Authors:  Shouyun Li; Xue Yang; Shuang Liu; Yirui Chen; Haiyan Xing; Kejing Tang; Zheng Tian; Yingxi Xu; Qing Rao; Min Wang; Jianxiang Wang
Journal:  Cell Death Dis       Date:  2021-06-11       Impact factor: 8.469

Review 9.  Classic and Variants APLs, as Viewed from a Therapy Response.

Authors:  Marie-Claude Geoffroy; Hugues de Thé
Journal:  Cancers (Basel)       Date:  2020-04-14       Impact factor: 6.639

10.  [Acute promyelocytic leukemia with STAT3-RARα fusion gene: a case report and literatures review].

Authors:  X X Xu; Z H Lyu; K Q Liu; Z S Meng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.